FDA Official Expects Tightened Vaccine Review
-
by Leroy Leo
-
by Mariam Sunny
November 22, 2024
-
2 min
The incoming US president's potential impact on the FDA's vaccine development and safety testing is raising concerns within the healthcare industry. Director Peter Marks suggests that the FDA may face increased scrutiny and is considering changes in vaccine messaging. Industry insiders fear changes after Trump's nomination of Robert F. Kennedy Jr. to lead the Department of Health and Human Services.
1. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, highlights potential changes in vaccine development under the new administration. 2. Concerns arise over increased scrutiny and changes in vaccine messaging. 3. Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services raises fears of regulatory changes. 4. Industry insiders worry about potential impact on the FDA and vaccine makers. 5. FDA workforce concerns, transparency in vaccine development, and leadership changes are key points.
Listen Tab content
